Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CABG Medical goes into liquidation after Holly Graft setbacks:

This article was originally published in Clinica

Executive Summary

CABG Medical has ceased trading after shareholders overwhelmingly approved plans to liquidate and dissolve the company. An initial distribution of $1.47 per share will be made this month and a second distribution, which could range up to $0.04 per share, will take place after the firm completes the shutdown of its Minneapolis, Minnesota-based operations. The company's stock had been offered at an initial price of $5.50 per unit, when it made its debut on the stock market at the end of 2004. The decision to close down came in February after the firm's clinical trials of its Holly Graft synthetic heart bypass graft suffered from a string of setbacks.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT051551

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel